



SensoLyte[®] 520 HIV-1 Protease Assay Kit

Fluorimetric

Revision Number: 1.1	Last updated: October 2014
Catalog #	AS-71147
Kit Size	100 assays (96-well) or 500 assays (384-well)

- **Convenient Format:** Complete kit including all the assay components.
- **Optimized Performance:** Optimal conditions for the detection of HIV-1 protease activity.
- **Enhanced Value:** Less expensive than the sum of individual components.
- **High Speed:** Minimal hands-on time.
- **Assured Reliability:** Detailed protocol and references are provided.

Kit Components, Storage and Handling

Component	Description	Quantity
Component A	HIV-1 protease FRET substrate	120 µL
Component B	HiLyte Fluor [™] 488, fluorescence reference standard Ex/Em=490 nm/520 nm	100 µM, 5 µL
Component C	Pepstatin A, a characterized HIV-1 protease inhibitor	27.4 µg powder
Component D	2X Assay buffer	20 mL
Component E	Stop solution	10 mL
Component F	DMSO	50 µL
Component G	DTT	1 M, 150 µL

Other Materials Required (but not provided)

- **HIV-1 protease:** HIV-1 protease can be produced either from *E. coli*² or by chemical synthesis. AnaSpec provides active recombinant HIV-1 protease (Cat#72028-5).
- **Microplate:** Black, flat-bottom 96-well or 384-well plate with non-binding surface.
- **Fluorescence microplate reader:** Capable of excitation at 490 nm and emission at 520 nm.


Storage and Handling

- Store all kit components at -20°C
- Protect Components A and B from light and moisture

Introduction

The 10~12 kD aspartic protease of human immunodeficiency virus-1 (HIV-1) is required for the post-translational cleavage of the precursor polyproteins, Pr^{gag} and Pr^{gag-pol}.¹ These cleavages are essential for the maturation of HIV infectious particles. Thus, the protease becomes one of the key targets for developing anti-AIDS drugs.

The Sensolyte[®] 520 HIV-1 protease assay kit provides a convenient assay for high throughput screening of HIV-1 protease inhibitors and continuous quantification of HIV-1 protease activity using a HiLyte Fluor[™]488/QXL[™]520 fluorescence resonance energy transfer (FRET) peptide. The sequence of this FRET peptide is derived from the native p17/p24 cleavage site on Pr^{gag} for HIV-1 protease. In the FRET peptide, the fluorescence of HiLyte Fluor[™]488 is quenched by QXL[™]520 until this peptide is cleaved into two separate fragments by HIV-1 protease (Scheme 1). Upon cleavage, the fluorescence of HiLyte Fluor[™]488 is recovered, and can be monitored at excitation/emission = 490 nm/520 nm. With excellent fluorescence quantum yield and longer excitation and emission wavelength, the fluorescence signal of HiLyte Fluor[™]488 is less interfered by the autofluorescence of cell components and test compounds. The assay can detect as low as 250 ng/mL active HIV-1 protease.



Scheme 1. Proteolytic cleavage of HiLyte Fluor[™]488/QXL[™]520 FRET peptide by HIV-1 protease.

Protocol

Note 1: For instrument calibration, refer to [Appendix II](#).

Note 2: Warm up all the kit components until thawed at room temperature before starting the experiments.

Note 3: Please choose protocol A or B based on your needs.

Protocol A. Screen HIV protease inhibitors using purified HIV-1 protease

1. Prepare working solutions.

1.1 1X Assay buffer: Prepare 1X assay buffer according to Table 1. Prepare this DTT-containing 1X assay buffer fresh for each experiment.

Table 1. 1X Assay buffer for one 96-well plate (100 assays).

©AnaSpec, Inc. • 34801 Campus Dr. • Fremont, CA 94555
Tel 800-452-5530 • 510-791-9560 • service@anaspec.com • www.anaspec.com

Components	Volume
2X assay buffer (Component D)	5 mL
1 M DTT (1000X, Component G)	10 μ L
Deionized water	5 mL
Total volume	10 mL

- 1.2 HIV-1 protease substrate solution: Prepare HIV-1 protease substrate solution according to Table 2. Mix the reagents well. Prepare fresh substrate solution for each experiment.

Table 2. HIV-1 protease substrate solution for one 96-well plate (100 assays).

Components	Volume
HIV-1 protease substrate (50X, Component A)	100 μ L
1X Assay buffer	4.9 mL
Total volume	5 mL

- 1.3 HIV-1 protease diluent: Dilute HIV protease to appropriate concentration in 1X assay buffer. The recommended volume for HIV-1 protease diluent is 40 μ L/assay (96-well plate) or 8 μ L/well (384-well plate). You may adjust the volume according to your preference.

Note: Prepare enzyme diluent right before use. Do not vortex enzyme. Prolonged storage of diluted enzyme or vigorously vortexing will denature the enzyme. Preserve the enzyme on ice.

- 1.4 Test compound: Dilute test compounds with deionized water or appropriate vehicle. The recommended volume for diluted test compound is 10 μ L/assay (96-well) or 2 μ L/well (384-well plate). You may adjust the volume according to your preference.

- 1.5 Pepstatin A⁴ (control inhibitor): add 20 μ L of DMSO (Component F) into one vial of Pepstatin A (Component C) to get a concentration of 2 mM. Vortex to dissolve it completely. Dilute 2 mM Pepstatin A to 2 μ M in deionized water. Prepare 30 μ L (96-well plate) or 6 μ L (384-well plate) per well of 2 μ M pepstatin A.

Note: The 2 mM Pepstatin A should be stored at -20°C for further use. The 2 μ M Pepstatin A is not stable, and should be prepared freshly for each experiment.

2. Set up enzymatic reaction.

- 2.1 Add test compounds and HIV-1 protease diluent into microplate. The suggested total volume of HIV-1 protease diluent plus test compound is 50 μ L, for example 40 μ L of protease diluent and 10 μ L of test compound. The suggested total volume of HIV-1 protease plus test compound for a 384-well plate is 10 μ L, for example 8 μ L of protease diluent and 2 μ L of test compound. You may adjust the volume according to your preference.

- 2.2 Set up the following controls at the same time:

- Positive control contains HIV-1 protease diluent without test compound.
- Inhibitor control contains HIV-1 protease diluent and known inhibitor, Pepstatin A.
- Vehicle control contains HIV-1 protease diluent and vehicle used to deliver test compound (e.g. DMSO).
- Test compound control contains assay buffer and test compound. Some test compounds have strong autofluorescence and may give false results.

- Substrate control contains assay buffer.

2.3 Using the assay buffer (Component D), bring the total volume of all controls to 50 µL (96-well plate) or 20 µL (384-well plate).

2.4 Incubate the plate at the desired temperature for enzymatic reaction for 10-15 min. In the mean time, also incubate the HIV-1 protease substrate solution at the same temperature.

3. Initiate the enzymatic reaction.

3.1 Add 50 µL (96-well plate) or 10 µL (384-well plate) per well of HIV-1 protease substrate solution. Mix the reagents completely by shaking the plate gently for 30-60 seconds.

3.2 Measure fluorescence signal:

- For kinetic reading: Immediately start measuring fluorescence intensity at Ex/Em=490 nm/520 nm continuously and record data every 5 minutes for 30 to 60 minutes.
- For end-point reading: Incubate the reaction at room temperature for 30 to 60 minutes. Keep the plate from direct light. Optional: Add 50 µL/well (96-well plate) or 10 µL/well (384-well plate) of stop solution (Component E). Mix the reagents. Measure fluorescence intensity at Ex/Em=490 nm/520 nm.

Note: If stop solution looks cloudy, warm it up in 37°C water bath to dissolve the precipitate.

3.3 Data analysis: Refer to Appendix I.

Protocol B. Measure HIV-1 protease activity in biological samples.

1. Prepare working solutions.

1.1 HIV-1 protease substrate solution: Prepare HIV-1 protease substrate solution according to Table 3. Mix the reagents well. Prepare fresh substrate solution for the experiment.

Table 3. HIV-1 protease substrate solution for one 96-well plate (100 assays).

Components	Volume
HIV-1 protease substrate (50X, Component A)	100 µL
1 M DTT (1000X, Component G)	5 µL
2X Assay buffer (Component D)	4.9 mL
Total volume	5 mL

2. Set up enzymatic reaction.

2.1 Add 50 µL/well (96-well plate) or 10 µL/well (384-well plate) of HIV-1 protease containing biological sample.

2.2 Set up the following controls at the same time:

- Positive control contains HIV-1 protease positive sample.
- Negative control contains biological sample without HIV-1 protease.
- Substrate control contains deionized water.

2.3 Using the assay buffer (Component D), bring the total volume of all controls to 50 μL (96-well plate) or 20 μL (384-well plate).

3. Initiate the enzymatic reaction.

3.1 Add 50 μL /well (96-well plate) or 10 μL /well (384-well plate) of HIV-1 protease substrate solution. Mix the reagents completely by shaking the plate gently for 30-60 seconds.

3.2 Measure fluorescence signal:

- For kinetics reading: Immediately start measuring fluorescence intensity at Ex/Em=490 nm/520 nm continuously and record data every 5 minutes for 30 to 60 minutes.
- For end-point reading: Incubate the reaction at room temperature for 30 to 60 minutes. Keep the plate from direct light. Optional: Add 50 μL /well (96-well plate) or 10 μL /well (384-well plate) of stop solution (Component E). Measure fluorescence intensity at Ex/Em=490 nm/520 nm.

3.3 Data analysis: Refer to Appendix I.

Appendix I. Data Analysis

- The fluorescence reading from the substrate control well is the background fluorescence. This background reading has to be subtracted from the readings of the other wells. This reading is the relative fluorescence unit (RFU).
- For kinetics reading:
 - Plot data as RFU versus time for each sample. If you want to convert the RFU to the concentration of the product of enzymatic reaction, refer to Appendix II for setting up fluorescence reference standard.
 - Determine the range of initial time points during which the reaction is linear. 10-15% conversion appears to be the optimal range.
 - Obtain the initial reaction velocity (V_0) in RFU/min. Determine the slope of the linear portion of the data plot.
 - A variety of data analyses can be done, e.g., determining inhibition %, EC_{50} , IC_{50} , K_m , K_i , etc.
- For endpoint reading:
 - Plot data as RFU versus the concentration of test compounds.
 - A variety of data analyses can be done, e.g., determining inhibition %, EC_{50} , IC_{50} , etc.

Appendix II: Instrument calibration

- HiLyte FluorTM488 fluorescence reference standard: dilute 100 μ M HiLyte FluorTM488 (Component B) to 1 μ M in 1X assay buffer (refer to protocol A Step 1.1 for preparation). Do 2-fold serial dilutions to get concentrations of 500, 250, 125, 62.5, 31.25 and 15.63 nM, include an assay buffer blank. Add 50 μ L/well of these serially diluted HiLyte FluorTM488 reference solutions into the 96-well plate or 10 μ L/well into the 384-well plate.
- Add 50 μ L/well (96-well plate) or 10 μ L/well (384-well plate) of HIV-1 protease substrate solution (refer to protocol A step 1.2 for preparation).

Note: The HIV-1 protease substrate solution should be added to the HiLyte FluorTM488 reference standard to correct the fluorescence inner filter effect.
- Optional: If the stop solution (Component E) was added into the enzymatic reaction before taking the end-point reading, the same volume of stop solution should be added to reference standard wells for better comparison.
- Measure the fluorescence intensity of the reference standard wells at Ex/Em=490 nm/520 nm. Use the same setting of sensitivity as used in the enzyme reaction.
- Plot HiLyte FluorTM 488 fluorescent reference standard as RFU (relative fluorescent unit) versus concentration as Figure 1.

Note: The final concentrations of HiLyte FluorTM488 reference standards are 500, 250, 125, 62.5, 31.25, 15.63, 7.81, and 0 nM. This reference standard is used to calibrate the variation of different instruments and different batch of experiments. It is also an indicator of the amount of final product of the HIV-1 protease enzymatic reaction.




Figure 1. HiLyte FluorTM488 reference standard. HiLyte FluorTM488 was diluted in assay buffer containing HIV-1 protease substrate, and fluorescence signal was measured at Ex/Em=485 \pm 20 nm/528 \pm 20 nm (FLx800, Bio-Tek Instruments).

References

1. S. Seelmeier, H. et al. *Proc.Natl.Acad.Sci.U.S.A* 85, 6612-6616 (1988).
2. H. Gehringer et al. *J.Virol.Methods* 109, 143-152 (2003).
3. J. Schneider and S. B. Kent, *Cell* 54, 363-368 (1988).